Somatorelin

DB12656InvestigationalProtein Based Therapies

Somatorelin is a synthetic version of growth hormone-releasing hormone used in the diagnosis of growth hormone deficiency. Somatorelin has been used in trials studying the treatment of Aging, Elderly, Sleep Disorders, Hormone Deficiency, and Mild Cognitive Impairment.

Mechanism
Curator reviewed
Also known as
GHRH · GHRH(1-44) AMIDE · GHRH(1-44)NH2 · growth hormone releasing hormone, 1-44 human amide · GROWTH HORMONE-RELEASING FACTOR (HUMAN)
Code names
GRF 1-44

Resolves to

Compound
UNII4UR7N9Z9MMCAS83930-13-6
Clinical / RWD
RxNorm236901ATCV04CD05
Targets
Q02643GHRHR

What you can answer from here — as of July 21, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
3ContraindicationsEach with its own population and attribute set
Sign in
1Marketed productAcross 1 country and 1 labeller
Sign in
1ATC codeIncluding every combination product, plus 13 drug categories
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Somatorelin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In